135 results
6-K
TAK
Takeda Pharmaceutical Co
2 Feb 24
Current report (foreign)
6:16am
expenses
Research and development expenses
Amortization and impairment losses on intangible assets associated with products
Other operating income
Other … ). The increase was mainly due to the depreciation of Japanese yen partially offset by various cost efficiencies.
Research and Development (R&D
6-K
TAK
Takeda Pharmaceutical Co
1 Feb 24
Current report (foreign)
6:06am
CER
Amount of Change
% Change
Revenue
Cost of sales
Selling, general and administrative expenses
Research and development expenses
Amortization … yen partially offset by various cost efficiencies.
Research and Development (R&D) expenses
R&D expenses were JPY 534.1 billion (JPY +61.7 billion
6-K
TAK
Takeda Pharmaceutical Co
16 Jan 24
Current report (foreign)
6:01am
, President & CEO:
Christophe Weber
Representative Director, President:
Daisuke Izutsu
(4) Business description
Research and development
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
14 Dec 23
Current report (foreign)
6:01am
governance, environmental and social initiatives, corporate and financial strategy, research and development, capital policy, business performance … management policy, sustainability matters, managerial and financial strategies, research and development, capital policy, financial performance
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
30 Nov 23
Current report (foreign)
6:01am
not meet the primary endpoint in a phase 3 study for ALOFISEL®. These events highlight the inherent risk in research and development
6-K
oz8c1za x62jkdm4wx
30 Oct 23
Current report (foreign)
6:02am
6-K
g4wby
26 Oct 23
Current report (foreign)
6:20am
6-K
xjkjr9cn
1 Aug 23
Current report (foreign)
6:10am
6-K
08zyznlt9 gflpl
27 Jul 23
Current report (foreign)
6:05am
6-K
EX-99.1
8rhx 46z3hioapfw87
12 Jul 23
Current report (foreign)
6:07am
144
ylwd 3klt2pd
10 Jul 23
Notice of proposed sale of securities
6:09am
6-K
EX-99.1
8qly8e2b
6 Jul 23
Current report (foreign)
6:18am
S-8
e04t2q800y1zid5zugx
28 Jun 23
Registration of securities for employees
6:35am
6-K
EX-99.1
zf8t09xkdz
23 Jun 23
Current report (foreign)
6:13am
6-K
goipv
30 May 23
Current report (foreign)
6:20am
6-K
EX-99.1
bijt5 rihszlc
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
zwawypw7m9j
30 May 23
Current report (foreign)
6:14am
6-K
EX-99.1
11pk2xklk2whl
30 May 23
Current report (foreign)
6:11am
6-K
365trgnzjmc9etx45
11 May 23
Current report (foreign)
6:07am